JonesResearch analyst Soumit Roy upgraded Monopar Therapeutics to Buy from Hold with a $2 price target after the company announced initiation of the Phase 1 dosimetry trial in Australia. The analyst cites the improving biotech sector and continued investor interest in the radiopharma space for the upgrade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics Begins Phase 1 Cancer Imaging Trial
- Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
- Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
- Monopar Therapeutics reports Q4 EPS (12c) vs (22c) last year
- Is MNPR a Buy, Before Earnings?
